Q2 FY27 results analysis · November 05, 2026
Ipca Laboratories Q2 FY27 Results Analysis: PAT Jumps 33%, EBITDA Margin Expands 128 bps (IPCALAB)
+32.8%PAT year on year, Rs. 375.13 Cr
Source: Quarterly results filing (NSE)
Quick summary
Ipca Laboratories Ltd's Q2 FY27 numbers came in strong, with revenue of Rs. 2,909.94 Cr (+13.79% YoY) and PAT growth of +32.77% YoY. Here's a quick read of what worked, what to watch, and what management said.
Quick Details
| Results date | November 05, 2026 |
|---|---|
| Revenue (Q2) | Rs. 2,909.94 Cr (+13.79% YoY) |
| PAT (Q2) | Rs. 375.13 Cr (+32.77% YoY) |
| EBITDA margin | 22.97% (+128 bps YoY) |
| EPS (Q2) | Rs. 14.79 (+23.81% YoY) |
Quarter Snapshot
IPCALAB delivered revenue growth of 13.79% YoY with EBITDA margin up 128 bps to 22.97% and owners' PAT up 32.77%, tracking on or ahead of every derivable FY27 guidance metric including the ~23% margin target management had cautioned could peak in Q2. The main blemishes are cash conversion (H1 CFO/PAT 0.738x) from a receivables and inventory build, a 6.94% decline in export APIs, and subsidiaries' 4.50% top-line growth; H2 requires only ~11-15% revenue growth and a ~23.08% margin to meet full-year guidance.
Q2 FY27 Expectations vs Results
| Driver | Expected before results | What happened | Verdict |
|---|---|---|---|
| Revenue vs raised 14–16% guide | "revenue tailwinds intact against a tougher base" | H1 +17.09%; Q2 +13.79% | Played out |
| Q2 margin hold (~23% guide) — "the contested question" vs freight/materials | margin under visible pressure | Q2 22.97% (+128 bps YoY, above Q1's 22.88%) | Played out |
| FX tailwind persisting "at least the next two quarters" | rupee in Rs.95–96 band all quarter | Filing silent on FX narrative; forex line favourable | Partially |
| Institutional run-rate ex-slip vs Rs.260–300 Cr | test vs ~Rs.72 Cr underlying | Q2 Rs.115.76 Cr; H1 Rs.235.51 Cr | Played out |
| Unichem Q2 print tests held guidance | 12–13% margin band at risk | Unichem-specific data not disclosed; subsidiaries' aggregate +4.50% | Not observable |
| Domestic share-lag risk vs a 12–13.5% IPM market | "second consecutive quarter of share lag is the risk" | Domestic formulations +13.57% Q2 (above the cited IPM range); IQVIA share not in filing | Partially |
| Pre-registered one-time items | none pre-flagged | Filing's Rs.24.26 Cr provision confirmed and normalized | Confirmed from filing |
Read our full results preview.
Management Guidance vs Delivery
| What management said | Where | What happened | Verdict |
|---|---|---|---|
| Consolidated revenue growth 14–16% FY27 | Q1 FY27 earnings call (raised from 12–13%) | H1 +17.09%; Q2 +13.79% | On Track |
| Consolidated EBITDA margin ~23% FY27 (company basis) | Q1 FY27 earnings call (raised from 22%) | Q2 22.97%; H1 22.92% | On Track |
| Domestic branded ~12% growth FY27 | Q1 FY27 earnings call | Q2 +13.57%; H1 +13.10% | On Track |
| Exports 12–13% growth (INR) FY27 | Q1 FY27 earnings call | Q2 standalone export income +16.96% (Rs.951.39 Cr); H1 +24.65% (Rs.1,886.78 Cr) | On Track |
| Institutional Rs.260–300 Cr FY27 | Q1 FY27 earnings call | H1 Rs.235.51 Cr already near the full-year band's lower half | On Track |
| Capex Rs.700–800 Cr FY27 | Q1 FY27 earnings call | H1 Rs.442.81 Cr | On Track |
| LT debt ~Rs.70 Cr term loan at FY27-end | Q1 FY27 earnings call | Non-current borrowings Rs.67.35 Cr at 30 Sep 2026 | On Track |
| "Standalone Net Profit… up 27%"; "Consolidated Net Profit… up 33%" (after exceptionals) | Q2/H1 FY27 press release | 387.29 (+27.09%) and 375.13 (+32.77%) | Confirmed |
| Q2 could be a peak-margin quarter (domestic slows in H2) | Q2 FY26 earnings call | Q2 FY27 margin 22.97% > Q1's 22.88%; caution not borne out this quarter — for now | Confirmed the opposite |
| Margin improvement of ~1% FY27 / ~23% level | Q4 & Q1 FY27 calls | +128 bps YoY already in H1 | On Track |
Key Investment Insights
Key Positives
- Consolidated revenue grew 13.79% YoY to Rs.2,909.94 Cr; H1 revenue grew 17.09% to Rs.5,698.04 Cr
- Management-basis EBITDA margin expanded 128 bps YoY to 22.97%, above Q1 FY27's 22.88% and against management's ~23% FY27 guidance
- Consolidated owners' PAT grew 32.77% YoY to Rs.375.13 Cr; normalized PAT grew 20.86%
- Formulations grew 19.73% YoY; export institutional formulations +45.27% (H1 Rs.235.51 Cr, +71.32%) and domestic APIs +56.12%
- Standalone revenue grew 16.85% YoY, faster than subsidiaries' aggregate +4.50% — growth is parent-led
- Finance costs fell 35.90% YoY to Rs.12.57 Cr; borrowings fell Rs.77.69 Cr in H1 to Rs.626.25 Cr with a net cash position of Rs.484.66 Cr
- H2 revenue needed to meet FY27 guidance is only +10.83% to +14.87% YoY, and H2 margin needed is ~23.08% — both on track
- FCF of Rs.130.51 Cr (CFO Rs.573.32 Cr less capex Rs.442.81 Cr) despite working-capital build
Risk Factors
- H1 CFO/PAT of 0.738x and CFO/EBITDA of 0.439x, driven by a Rs.206.78 Cr inventory build and Rs.364.57 Cr receivables increase
- Trade receivables grew 18.90% and inventories Rs.206.78 Cr in six months, both outpacing 17.09% H1 revenue growth
- Export APIs declined 6.94% YoY — the only declining revenue line
- Subsidiaries' aggregate revenue grew only 4.50% YoY; consolidated owners' PAT sat Rs.12.16 Cr below standalone PAT due to NCI swing and associates
- Other expenses grew 16.34% YoY, faster than revenue, consistent with flagged freight/logistics cost pressure
- Effective tax rate rose ~84 bps YoY to 28.44%, with total tax +43.97% vs PBT +39.73%
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Companies on this page
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.